TradingKey

关于 Agios Pharmaceuticals Inc 公司

Agios Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于为患有罕见疾病的患者开发和提供变革性疗法。该公司为患有 PK 缺乏症的成年人销售一流的丙酮酸激酶 (PK) 激活剂，这是首个用于治疗衰弱性溶血性贫血的疾病改良疗法。其基因定义疾病 (GDD) 产品组合中的主打候选产品 PYRUKYND (Mitapivat) 是野生型和多种突变型丙酮酸激酶 (PK) 酶的激活剂，用于治疗溶血性贫血。Mitapivat 是一种口服小分子，是丙酮酸激酶 R (PKR) 酶的强效激活剂。此外，该公司还在正在进行的临床试验中评估 mitapivat 对 α 和 β 地中海贫血和镰状细胞病 (SCD) 的治疗效果。该公司还在开发 AG-946，一种临床阶段的 PKR 酶口服激活剂，用于治疗溶血性贫血和包括 SCD 在内的其他适应症。

公司简介

公司代码AGIO

公司名称Agios Pharmaceuticals Inc

上市日期Jul 24, 2013

CEOMr. Brian M. Goff

员工数量486

证券类型Ordinary Share

年结日Jul 24

公司地址88 Sidney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02139

电话16176498600

网址https://www.agios.com/

公司代码AGIO

上市日期Jul 24, 2013

CEOMr. Brian M. Goff

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Brian M. Goff

Chief Executive Officer, Director

111.92K

+21.20%

Dr. Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

61.27K

+7.52%

Ms. Cecilia Jones

Chief Financial Officer

30.05K

+16.34%

Ms. Tsveta Milanova

Chief Commercial Officer

26.12K

+14.11%

Dr. Maykin Ho, Ph.D.

Independent Director

17.03K

+14.22%

Ms. Cynthia Smith

Independent Director

10.11K

+26.53%

Mr. Jeffrey D. (Jeff) Capello, CPA

Independent Director

6.07K

+207.34%

Mr. Krishnan Viswanadhan

Chief Corporate Development and Strategy Officer

--

Jay Backstrom

Director

--

Mr. Christopher Taylor

Vice President - Investor Relations and Corporate Communications

--

名称

名称/职务

职务

持股

持股变动

Mr. Brian M. Goff

Chief Executive Officer, Director

111.92K

+21.20%

Dr. Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head - Research and Development

61.27K

+7.52%

Ms. Cecilia Jones

Chief Financial Officer

30.05K

+16.34%

Ms. Tsveta Milanova

Chief Commercial Officer

26.12K

+14.11%

Dr. Maykin Ho, Ph.D.

Independent Director

17.03K

+14.22%

Ms. Cynthia Smith

Independent Director

10.11K

+26.53%

收入明细

FY2025Q1

FY2024

FY2023

FY2022

FY2020

FY2019

暂无数据

地区USD

名称

营收

占比

United States

8.73M

0.00%

业务

地区

暂无数据

股东统计

更新时间: 7月10日周四

持股股东

股东类型

持股股东

占比

Farallon Capital Management, L.L.C.

9.81%

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

7.57%

Bellevue Asset Management AG

6.05%

State Street Global Advisors (US)

4.22%

Other

62.73%

持股股东

占比

Farallon Capital Management, L.L.C.

9.81%

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

7.57%

Bellevue Asset Management AG

6.05%

State Street Global Advisors (US)

4.22%

Other

62.73%

股东类型

持股股东

占比

Investment Advisor

49.06%

Hedge Fund

25.91%

Investment Advisor/Hedge Fund

25.62%

Private Equity

2.65%

Research Firm

2.40%

Individual Investor

1.68%

Pension Fund

0.46%

Bank and Trust

0.33%

Sovereign Wealth Fund

0.25%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

463

62.80M

108.44%

-4.88M

2025Q1

483

63.23M

109.19%

-5.15M

2024Q4

462

62.61M

109.28%

-3.00M

2024Q3

454

61.83M

108.70%

-5.23M

2024Q2

446

61.36M

108.10%

-8.04M

2024Q1

418

65.03M

115.74%

-790.05K

2023Q4

400

62.85M

112.46%

-374.07K

2023Q3

410

61.92M

111.10%

-5.01M

2023Q2

431

62.18M

111.88%

-5.52M

2023Q1

447

61.81M

111.31%

-8.35M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Farallon Capital Management, L.L.C.

5.70M

9.84%

+26.00K

+0.46%

Mar 31, 2025

The Vanguard Group, Inc.

5.59M

9.66%

-26.73K

-0.48%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.40M

7.59%

+17.29K

+0.39%

Mar 31, 2025

State Street Global Advisors (US)

2.45M

4.23%

+297.20K

+13.81%

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.25M

3.89%

-129.04K

-5.42%

Mar 31, 2025

Erste Asset Management GmbH

2.23M

3.85%

+220.00K

+10.95%

Mar 31, 2025

Commodore Capital LP

2.19M

3.77%

+2.19M

--

Mar 31, 2025

Armistice Capital LLC

2.05M

3.54%

-216.30K

-9.55%

Mar 31, 2025

Macquarie Investment Management

1.85M

3.2%

+165.55K

+9.83%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

WisdomTree BioRevolution Fund

1.94%

Virtus LifeSci Biotech Products ETF

1.86%

ALPS Medical Breakthroughs ETF

1.3%

Harbor Human Capital Factor US Small Cap ETF

0.86%

WisdomTree US SmallCap Fund

0.5%

Invesco NASDAQ Future Gen 200 ETF

0.47%

JPMorgan Healthcare Leaders ETF

0.45%

SPDR S&P Biotech ETF

0.42%

JPMorgan Fundamental Data Science Small Core ETF

0.38%

Global X Aging Population ETF

0.36%

WisdomTree BioRevolution Fund

占比1.94%

Virtus LifeSci Biotech Products ETF

占比1.86%

ALPS Medical Breakthroughs ETF

占比1.3%

Harbor Human Capital Factor US Small Cap ETF

占比0.86%

WisdomTree US SmallCap Fund

占比0.5%

Invesco NASDAQ Future Gen 200 ETF

占比0.47%

JPMorgan Healthcare Leaders ETF

占比0.45%

SPDR S&P Biotech ETF

占比0.42%

JPMorgan Fundamental Data Science Small Core ETF

占比0.38%

Global X Aging Population ETF

占比0.36%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Agios Pharmaceuticals Inc

28.830USD

Agios Pharmaceuticals Inc

28.830

概览

公司

财务